| Literature DB >> 29854748 |
Hongmu Li1, Xifeng Lin2, Xun Ma3, Jun Tao2, Rongjun Zou2, Songran Yang4,5, Haibo Liu1, Ping Hua2.
Abstract
OBJECTIVE: The outcomes of biatrial ablation (BA) and isolated left atrial ablation (LA) in atrial fibrillation remain inconclusive. In this meta-analysis, we assess the currently available evidence to compare outcomes between BA and LA.Entities:
Mesh:
Year: 2018 PMID: 29854748 PMCID: PMC5949196 DOI: 10.1155/2018/3651212
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Selection of studies for the meta-analysis.
Figure 2Risk of bias in RCT studies.
Risk of bias in observational studies.
| Study | Selection | Comparability | Outcome | Quality score | ||||
|---|---|---|---|---|---|---|---|---|
| Assignment for treatment | Representative treatment group | Representative reference group | Comparable for 1, 2, 3, 4 | Comparable for 5, 6, 7, 8 | Assessment of outcome | Adequate follow-up | ||
| Gualis et al. 2016 | No | Yes | Yes | 1, 2 | 5, 8 | Yes | No | ★★★★★ |
| Liu et al., 2015 | No | Yes | Yes | 1, 2 | 5, 8 | No | Yes | ★★★★★ |
| Henn et al., 2015 | No | Yes | Yes | NR | 5, 6 | Yes | No | ★★★★ |
| Pecha et al., 2014 | No | Yes | Yes | 1, 2 | 5, 8 | Yes | NR | ★★★★★ |
| Jiang, 2014 | No | Yes | Yes | 1, 2 | 8 | Yes | No | ★★★★ |
| Soni et al., 2013 | No | Yes | Yes | 1, 2 | 8 | No | No | ★★★ |
| Pecha et al., 2014 | No | Yes | Yes | 1, 2 | 5, 6 | Yes | Yes | ★★★★★★ |
| Onorati et al., 2011 | No | Yes | Yes | 1, 2 | 5, 6, 8 | Yes | Yes | ★★★★★★★ |
| Kim et al., 2011 | No | Yes | Yes | 1, 2 | 7, 8 | Yes | No | ★★★★★ |
| Breda et al., 2011 | No | Yes | Yes | 1, 2 | 6, 8 | No | No | ★★★★ |
| Albage et al., 2011 | No | Yes | Yes | 1, 2 | 7 | Yes | No | ★★★★ |
| McCarthy et al., 2010 | No | Yes | Yes | 1, 2 | 8 | Yes | Yes | ★★★★★★ |
| Deneke et al., 2009 | No | Yes | Yes | 1, 4 | 6, 8 | Yes | Yes | ★★★★★★ |
| Geuzebroek et al., 2008 | No | Yes | Yes | 1, 2 | 5 | No | Yes | ★★★★ |
| Deneke et al., 2007 | No | Yes | Yes | 1, 4 | 8 | Yes | Yes | ★★★★★ |
| Ryan et al., 2004 | No | Yes | Yes | NR | 5, 6, 7, 8 | Yes | No | ★★★★★ |
| Guden et al., 2003 | No | Yes | Yes | 1, 2, 3 | NR | Yes | Yes | ★★★★★ |
| Takami et al., 1999 | No | Yes | Yes | 1, 2, 3 | 5, 7, 8 | Yes | Yes | ★★★★★★★ |
NR: no report; comparability variables: 1 = age; 2 = gender; 3 = body mass index; 4 = type of AF; 5 = Euro score; 6 = preoperative antiarrhythmic drugs; 7 = anatomic complexity (more than one artery and/or vein); 8 = single surgeon.
Characteristics of the studies that were initially included in the meta-analysis.
| First author | Year | Country | Study period | Type of study | Follow-up (MO) |
|
| Type of ablation | Lesion set | Cardiac operation |
|---|---|---|---|---|---|---|---|---|---|---|
| Gualis | 2016 | Spain | 2006–2011 | R | 36 | 67 | 83 | CY | PVI, LAA, RAA, TC, CS, WG | AVR AVP MVR MVP TVP |
|
| ||||||||||
| Liu | 2015 | China | 2012-2012 | R | 3–12R | 86 | 111 | RF | PVI, LAA, RAA | MVR DVR TVP |
|
| ||||||||||
| Henn | 2015 | USA | 2002–2014 | P, non-RCT | 5 years | 532 | 44 | RF | PVI, LAA, RAA, TC, CS, WG | AVR CABG MVR MVP TVP |
|
| ||||||||||
| Pecha | 2014 | Germany | 2008–2011 | R | 12 | 66 | 66 | RF, CY | LVI, LAA, CI, RAA, TC | CABG AVR MVR TVR |
|
| ||||||||||
| Jiang | 2014 | China | 2008–2012 | R | NR | 61 | 48 | RF | PVI, MV, LAA, RAA, TC, CS, WG | MVR MVP TVP |
|
| ||||||||||
| Soni | 2013 | USA | 2007–2011 | R | 12 | 91 | 214 | RF, CY, MW | PVI, PW, MI, LAA MM | AVR MVR CABG MVP TVP |
|
| ||||||||||
| Pecha | 2014 | Germany | 2003–2012 | R | 30 days | 131 | 463 | CY, RF | LVI, LAA, BLI, CI, RAA, TC | AVR AVP MVR MVP TVP CABG ASD VSD |
|
| ||||||||||
| Onorati | 2011 | Italy | 2003–2008 | P, non-RCT | 15 | 109 | 32 | RF | PVI MV LAA RAA TC CS WG | AVR AVP MVR MVP TVP |
|
| ||||||||||
| Kim | 2011 | South Korea | 2006–2009 | R | 26 ± 13.3 | 199 | 82 | CY | PVI, PW, MI, LAA, MM, CS | AVR AVP MVR MVP TVP CABG ASD VSD |
|
| ||||||||||
| Breda | 2011 | Brazil | 2003–2009 | R | 12.16 ± 10.89 | 15 | 15 | RF | PVI, PW, MI, LAA, MM | MVR MVP |
|
| ||||||||||
| Albage | 2011 | Sweden | 2005–2010 | P, non-RCT | 1–12R | 44 | 71 | CY | PVI, PW, MI, LAA, Maze III | AVR CABG MVP TVP MVR ASD MVP |
|
| ||||||||||
| McCarthy | 2010 | USA | 2004–2008 | P, non-RCT | 5–24R | 91 | 75 | RF, CY, cut-and-sew | PVI LAA RAA TC | AVR MVR TVP CABG |
|
| ||||||||||
| Deneke | 2009 | Germany | NR | R | 55 ± 17 | 64 | 66 | RF | PVI, PW, MI, LAA, Maze III | MVR, AVR, CABG |
|
| ||||||||||
| Wang | 2009 | China | 2004–2007 | P, RCT | 28 ± 5 | 150 | 149 | RF | PVI, PW, MI, LAA, CTI, MM | MVR AVR MVP TVR TVP AVP |
|
| ||||||||||
| Srivastava | 2008 | India | NR | P, RCT | 44 | 40 | 40 | RF, CY | PVI, PW, MI, LAA, Maze III | MVR AVR MVP TVR TVP AVP |
|
| ||||||||||
| Geuzebroek | 2008 | Netherlands | 1999–2005 | R | NR | 26 | 40 | RF | PVI, PW, MI, LAA, Maze III | MVR AVR MVP TVR TVP AVP |
|
| ||||||||||
| Deneke | 2007 | Germany | 1997–2005 | R | 21 | 106 | 116 | RF | PVI MV LAA RAA, MM | MVR MVP CABG AVR |
|
| ||||||||||
| Calo | 2006 | Italy | NR | P, RCT | 15 ± 5 (BA)/13 ± 6 (LA) | 39 | 41 | RF | PVI MV LAA RAA TC CS WG | NR |
|
| ||||||||||
| Ryan | 2004 | USA | 1996–2003 | R | 595 ± 750 days | 36 | 7 | RF, CY, cut-and-sew | PVI, PW, MI, LAA, Maze III | NR |
|
| ||||||||||
| Guden | 2003 | Turkey | 2001 | P, non-RCT | 10.9 ± 5.58 | 48 | 57 | RF | PVI, PW, MI, LAA, Maze III | AVR CABG MVP TVP MVR ASD MVP |
|
| ||||||||||
| Takami | 1999 | Japan | NR | R | 34.1 ± 11.3 (BA)/17.8 ± 3.8 (LA) | 30 | 20 | CY, cut-and-sew | PVI, PW, MI, LAA, CTI, Maze III | MVR, CABG, AVR, TVR |
MO: month; R: range; P: p retrospective observational; RCT: randomized, controlled trial; BA: biatrial ablation; LA: left atrial ablation; CY: cryoablation; RF: radiofrequency ablation; MW: microwave ablation; PVI: pulmonary vein isolation; LAA: left atrial appendage; RAA: right atrial appendage; TC: terminal crest; CS: coronary sinus; WG: Waterston's groove; MI: mitral isthmus; MM: modified maze; CI: cavotricuspid isthmus; PW: posterior wall; AVR: aortic valve replacement; AVP: aortic valvuloplasty; MVR: mitral valve replacement; MVP: mitral valvuloplasty; TVP: tricuspid valvuloplasty; CABG: coronary artery bypass grafting; ASD: atrial septal defect repair; VSD: ventricular septal defect repair; NR: no report.
Baseline characteristics of the included studies.
| First author | Age (BA/LA, years) | Male (BA/LA) | Diabetes (BA/LA) | Heart failure (BA/LA) | Cerebrovascular events (BA/LA) | Hypertension (BA/LA) | Type of AF |
|---|---|---|---|---|---|---|---|
| Gualis | 65.1 ± 10.2/71.6 ± 6.8 | 29/39 | 15/17 | 32/31 | 7/12 | NR | Permanent persistent |
| Liu | 49.87 ± 8.96/47.98 ± 8.64 | 21/23 | NR | NR | NR | NR | Permanent persistent |
| Henn | 64 ± 12 | NR | NR | NR | NR | NR | Permanent persistent |
| Pecha | 70.5 ± 7.3/70.1 ± 7.5 | 45/40 | 16/13 | NR | NR | NR | Paroxysmal persistent permanent |
| Jiang | 52.7 ± 4.9/50.7 ± 5.9 | 22/21 | 7/8 | 36/29 | 2/2 | 11/8 | Paroxysmal persistent permanent |
| Soni | NR | NR | NR | NR | NR | NR | Paroxysmal persistent permanent |
| Pecha | 59 ± 28/68 ± 12 | 54/116 | 16/40 | NR | NR | 67/118 | Paroxysmal persistent permanent |
| Onorati | 64 ± 9/65 ± 8 | 79/18 | 40/10 | NR | NR | 37/15 | Permanent persistent |
| Kim | 56.3 ± 12.0/52.1 ± 11.9 | 75/47 | 19/5 | NR | NR | 32/21 | Paroxysmal persistent permanent |
| Breda | 60.0 ± 8.07/46.3 ± 9.54 | 9/5 | NR | 10/6. | NR | NR | Permanent persistent |
| Albage | 64.9 ± 10.4/66.9 ± 6.7 | 34/54 | 4/11 | 17/28 | 2/7 | 10/27 | Paroxysmal persistent permanent |
| McCarthy | 68.7 ± 10.3/66.8 ± 12.1 | 42/88 | 13/22 | NR | NR | NR | Paroxysmal persistent permanent |
| Wang | 67 ± 8/69 ± 9 | NR | NR | NR | NR | NR | Permanent persistent |
| Deneke | 53.4 ± 10.8/54.2 ± 10.1 | 54/62 | NR | NR | NR | NR | Permanent persistent |
| Srivastava | 37.11 ± 11.12/36.03 ± 7.99 | 19/22 | NR | NR | NR | NR | Permanent persistent |
| Geuzebroek | 63.3 ± 7.9/61.1 ± 10.3 | 21/17 | NR | NR | NR | NR | Paroxysmal persistent permanent |
| Deneke | 68 ± 9 | NR | NR | NR | NN | NR | Paroxysmal persistent permanent |
| Calo | 57.9 ± 8.9/59.2 ± 9.1 | 26/26 | NR | NR | NR | 16/18 | Paroxysmal persistent permanent |
| Ryan | NR | NR | NR | NR | NR | NR | Paroxysmal persistent permanent |
| Guden | 52 ± 11/54 ± 9 | 14/23 | NR | NR | N | NR | Permanent persistent |
| Takami | 54.7 ± 8.8/58.3 ± 8.7 | 11/9 | NR | NR | NR | NR | Paroxysmal persistent permanent |
BA: biatrial ablation; LA: left atrial ablation; NR: no report.
Figure 3Restored SR at discharge, 6 months, and 12 months and beyond 1 year.
Figure 4Mortality within 30 days.
Figure 5Late mortality.
Figure 6Cerebrovascular events.
Figure 7Permanent pacemaker implantation.
Sensitivity and subgroup analyses.
| Endpoint | Restored SR at discharge | Restored SR at 12 months | Restored SR beyond 1 year | |||
|---|---|---|---|---|---|---|
| Overall | OR (95% CI) | Overall | OR (95% CI) | Overall | OR (95% CI) | |
|
| 0.46 | 1.37 (0.60, 3.11) | ||||
| RCT | 0.38 | 0.51 (0.12, 2.25) | Have no RCT studies | 0.69 | 1.25 (0.43, 3.65) | |
| Non-RCT | 0.4 | 1.17 (0.81, 1.68) | ||||
|
| ||||||
| <150 | 0.88 | 1.05 (0.56, 1.95) | 0.04 | 1.76 (1.02, 3.04) | 0.76 | 1.22 (0.24, 4.46) |
| >150 | 0.96 | 0.99 (0.66, 1.49) | 0.44 | 1.29 (0.67, 2.48) | 0.3 | 1.44 (0.73, 2.85) |
|
| ||||||
| Fixed-effect | 0.3 | 1.12 (0.90, 1.38) | 0.009 | 1.39 (1.09, 1.79) | 0.16 | 1.21 (0.92, 1.59) |
| Random-effect | 0.34 | 1.15 (0.86, 1.55) | 0.2 | 1.37 (0.85, 2.21) | 0.4 | 1.31 (0.70, 2.48) |
SR: sinus rhythm; RCT: randomized, controlled trial.